Carriers of parkin mutations have a more favourable disease course compared to sporadic PD patients: although onset is generally earlier, disease progression is significantly slower and the response to dopaminergic treatment better than in sporadic PD [18], [19]. Here, PRKN is linked to Parkinson disease.